Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

AbbVie, Gilead and Allergan 3-peat with September's top pharma TV spending
Fierce Pharma
Tue, 10/15/19 - 11:58 am
Tags:
DTC ads, television ads, AbbVie, Humira, Gilead Sciences, Truvada, Allergan, Botox
AbbVie Stays Busy While Working to Complete Allergan Acquisition
BioSpace
Fri, 10/11/19 - 10:34 pm
Tags:
AbbVie, Allergan, M&A, Skyrizi, Reata Pharmaceuticals
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
Fierce Pharma
Fri, 10/11/19 - 11:53 am
Tags:
ICER, AbbVie, Rinvoq, rheumatoid arthritis, JAK inhibitors
Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor
Endpoints
Fri, 10/11/19 - 10:40 am
Tags:
AbbVie, Principia Biopharma, PRN1008, pemphigus vulgaris
Reata buys drug rights back from AbbVie for $330M before readout
Biopharma Dive
Thu, 10/10/19 - 12:53 pm
Tags:
Reata Pharmaceuticals, AbbVie, bardoxolone methyl
Big Pharma giving more money to patient advocacy groups
Beckers Hospital Review
Wed, 10/9/19 - 11:14 pm
Tags:
Big Pharma, JNJ, AbbVie, Bristol-Myers Squibb, Pfizer, Merck, AstraZeneca, patient advocacy groups
Chasing AbbVie, Gilead files for approval of filgotinib in Japan
Fierce Biotech
Tue, 10/8/19 - 09:40 am
Tags:
Gilead Sciences, JAK inhibitors, Japan, filgotinib, Galapagos, AbbVie
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Yahoo/Reuters
Tue, 10/8/19 - 09:23 am
Tags:
ICER, drug pricing, AbbVie, Humira, Roche, Rituxan
Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report
Fierce Pharma
Fri, 10/4/19 - 12:44 pm
Tags:
Merck, Keytruda, Bristol-Myers Squibb, Pfizer, Eliquis, AbbVie, Humira
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
Fierce Pharma
Wed, 10/2/19 - 11:53 am
Tags:
ICER, JAK inhibitors, rheumatoid arthritis, AbbVie, Rinvoq, Pfizer, Xeljanz, Incyte, olumiant
FDA clears shorter treatment regimen for AbbVie's hep C treatment, Mavyret. Will patients benefit?
Endpoints
Mon, 09/30/19 - 10:42 am
Tags:
AbbVie, Mavyret, hepatitis C, FDA
FTC requests AbbVie, Allergan for more information on $63 billion deal
Reuters
Sat, 09/28/19 - 04:31 pm
Tags:
FTC, M&A, AbbVie, Allergan
AbbVie's premium bid for Allergan isn't enough for one investor, who's suing to block it
Fierce Pharma
Mon, 09/23/19 - 11:57 am
Tags:
AbbVie, Allergan, M&A
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
Sun, 09/22/19 - 11:10 pm
Tags:
JNJ, daratumumab, Urogen, Rhythm Pharmaceuticals, Anavex, Aravive Biologics, TrovaGene, Incyte, AstraZeneca, Roche, Amgen, Aslan, G1 Therapeutics, GSK, Calithera Biosciences, Seattle Genetics, Immunomedics, Checkpoint Therapeutics, Aileron Therapeutics, Genocea Biosciences, AbbVie, Zymeworks
Who will be the biggest pharma players in orphan drugs?
Pharmaforum
Sat, 09/7/19 - 06:25 pm
Tags:
orphan drugs, Roche, M&A, AbbVie, JNJ
Skyrizi looks ready to soar after strong launch
Biopharma Dive
Wed, 09/4/19 - 11:23 pm
Tags:
AbbVie, Skyrizi, psoriasis
Rova-T: the story of AbbVie’s multi-billion dollar failure
Pharmaforum
Wed, 09/4/19 - 10:12 am
Tags:
AbbVie, lung cancer, M&A, Stemcentrx, Rova-T
$5.8B for Nothing: AbbVie Shelves Stemcentryx Drug After Latest Flop
Xconomy
Thu, 08/29/19 - 10:33 am
Tags:
AbbVie, Stemcentryx, Rova-T
FDA issues safety warning for newer hepatitis C drugs following patient deaths
Biopharma Dive
Wed, 08/28/19 - 11:02 pm
Tags:
FDA, hepatitis C, FAERS, AbbVie, Mavyret, Merck, Zepatier, Gilead Sciences, Vosevi
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Endpoints
Wed, 08/28/19 - 12:38 pm
Tags:
Bristol-Myers Squibb, AbbVie, Empliciti, Celgene, Europe, relapsed or refractory multiple myeloma

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.